Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Ikena Oncology Inc (NQ: IKNA ) 1.710 +0.020 (+1.18%) Streaming Delayed Price Updated: 4:00 PM EDT, Aug 30, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Ikena Oncology Inc < Previous 1 2 Next > Ikena Oncology Reports Second Quarter 2024 Financial Results August 08, 2024 Strong financial position with $145 million in cash and investments at close of second quarter From Ikena Oncology, Inc. Via GlobeNewswire UPDATE – Ikena Oncology Announces Strategic Update May 28, 2024 From Ikena Oncology, Inc. Via GlobeNewswire Ikena Oncology Announces Strategic Update May 28, 2024 From Ikena Oncology, Inc. Via GlobeNewswire Ikena Oncology Reports First Quarter 2024 Financial Results and Corporate Update May 13, 2024 From Ikena Oncology, Inc. Via GlobeNewswire Ikena Oncology to Present at the Stifel 2024 Virtual Targeted Oncology Forum April 10, 2024 From Ikena Oncology, Inc. Via GlobeNewswire Ikena Oncology Reports Fourth Quarter and Full Year 2023 Financial Results March 12, 2024 From Ikena Oncology, Inc. Via GlobeNewswire Ikena Oncology to Participate in TD Cowen 44th Annual Health Care Conference February 27, 2024 From Ikena Oncology, Inc. Via GlobeNewswire Ikena Oncology Appoints Caroline Germa, M.D. as Chief Medical Officer February 21, 2024 From Ikena Oncology, Inc. Via GlobeNewswire Ikena Oncology Outlines Key Priorities and Provides Corporate Updates January 18, 2024 From Ikena Oncology, Inc. Via GlobeNewswire Ikena Oncology Shares Initial Positive and Differentiated Dose Escalation Data from IK-930 Phase I Trial and Reports Third Quarter 2023 Financial Results November 09, 2023 From Ikena Oncology, Inc. Via GlobeNewswire Ikena Oncology to Present at Multiple November 2023 Investor Conferences November 07, 2023 From Ikena Oncology, Inc. Via GlobeNewswire Ikena Oncology to Participate in September 2023 Investor Conferences September 05, 2023 From Ikena Oncology, Inc. Via GlobeNewswire Ikena Oncology Reports Second Quarter 2023 Financial Results and Corporate Update August 10, 2023 From Ikena Oncology, Inc. Via GlobeNewswire Ikena Oncology Acquires Pionyr Immunotherapeutics in All-Stock Transaction August 07, 2023 From Ikena Oncology, Inc. Via GlobeNewswire Ikena Oncology to Participate in Upcoming Investor Conferences May 24, 2023 From Ikena Oncology, Inc. Via GlobeNewswire Ikena Oncology Reports First Quarter 2023 Financial Results and Highlights Advancements Across Targeted Oncology Pipeline May 15, 2023 From Ikena Oncology, Inc. Via GlobeNewswire Ikena Oncology Announces $40 Million Underwritten Offering May 15, 2023 From Ikena Oncology, Inc. Via GlobeNewswire Ikena Oncology to Participate in the Stifel 2023 Virtual Targeted Oncology Days April 20, 2023 From Ikena Oncology, Inc. Via GlobeNewswire Ikena Oncology Shares Differentiation Profile of IK-930, a Novel Hippo-Pathway Inhibitor, Including Projected Therapeutic Index Advantages and Breadth of Patient Populations at AACR 2023 Annual Meeting April 17, 2023 From Ikena Oncology, Inc. Via GlobeNewswire Ikena Oncology Reports Fourth Quarter and Full Year 2022 Financial Results March 14, 2023 From Ikena Oncology, Inc. Via GlobeNewswire Ikena Oncology Presents Preclinical Data on IK-595, Best-in-Class Next-Generation MEK-RAF Complex Inhibitor, in Plenary Session at AACR Special Conference on RAS Targeting March 07, 2023 From Ikena Oncology, Inc. Via GlobeNewswire Ikena Oncology Receives FDA Fast Track Designation for Novel AHR Antagonist IK-175 in Combination with Nivolumab to Treat Urothelial Carcinoma March 06, 2023 From Ikena Oncology, Inc. Via GlobeNewswire Ikena Oncology to Participate in Cowen 43rd Annual Health Care Conference February 28, 2023 From Ikena Oncology, Inc. Via GlobeNewswire Ikena Oncology Appoints Owen Hughes as Board Chair December 19, 2022 From Ikena Oncology, Inc. Via GlobeNewswire Ikena Oncology Announces New Program in Next-Generation MEK-RAF Inhibition and Provides Corporate Update November 28, 2022 From Ikena Oncology, Inc. Via GlobeNewswire Ikena Oncology to Participate in the Piper Sandler 34th Annual Healthcare Conference November 22, 2022 From Ikena Oncology, Inc. Via GlobeNewswire Ikena Oncology Announces Initial Clinical Data from IK-175 Program in Urothelial Carcinoma November 10, 2022 From Ikena Oncology, Inc. Via GlobeNewswire UPDATE -- Ikena Oncology Reports Third Quarter 2022 Financial Results and Provides a Corporate Update November 07, 2022 From Ikena Oncology, Inc. Via GlobeNewswire Ikena Oncology Reports Third Quarter 2022 Financial Results and Provides a Corporate Update November 07, 2022 From Ikena Oncology, Inc. Via GlobeNewswire Ikena Oncology Presents Preclinical Data at the 34th EORTC-NCI-AACR Symposium on Novel TEAD Inhibitor, IK-930, Combating Therapeutic Resistance October 26, 2022 From Ikena Oncology, Inc. Via GlobeNewswire < Previous 1 2 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.